KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$61.7 million.

  • Supernus Pharmaceuticals' Cash from Operations fell 21521.67% to -$61.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.9 million, marking a year-over-year decrease of 5833.35%. This contributed to the annual value of $172.0 million for FY2024, which is 5479.23% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Cash from Operations is -$61.7 million, which was down 21521.67% from $58.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Cash from Operations high stood at $71.1 million for Q2 2022, and its period low was -$61.7 million during Q3 2025.
  • Moreover, its 5-year median value for Cash from Operations was $36.2 million (2021), whereas its average is $29.2 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Cash from Operations surged by 104193.4% in 2023 and then tumbled by 21521.67% in 2025.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Cash from Operations stood at $48.8 million in 2021, then plummeted by 43.47% to $27.6 million in 2022, then soared by 63.1% to $45.0 million in 2023, then fell by 1.23% to $44.4 million in 2024, then plummeted by 238.86% to -$61.7 million in 2025.
  • Its last three reported values are -$61.7 million in Q3 2025, $58.5 million for Q2 2025, and $30.6 million during Q1 2025.